Oncotarget

Research Papers:

The survival benefit and safety of No. 12a lymphadenectomy for gastric cancer patients with distal or total gastrectomy

Kun Yang, Hai-Ning Chen, Kai Liu, Wei-Han Zhang, Xin-Zu Chen, Xiao-Long Chen, Zong-Guang Zhou and Jian-Kun Hu _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:18750-18762. https://doi.org/10.18632/oncotarget.7930

Metrics: PDF 559 views  |   HTML 878 views  |   ?  


Abstract

Kun Yang1,2,*, Hai-Ning Chen1,*, Kai Liu1,2, Wei-Han Zhang1,2, Xin-Zu Chen1,2, Xiao-Long Chen1,2, Zong-Guang Zhou1, Jian-Kun Hu1,2

1Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, China

2Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, China

*These authors contributed equally to this work

Correspondence to:

Jian-Kun Hu, e-mail: hujkwch@126.com

Keywords: gastric cancer, gastrectomy, No.12a lymph nodes, survival, safety

Received: October 04, 2015     Accepted: January 29, 2016     Published: March 05, 2016

ABSTRACT

There has still not been a consensus in aspects of survival benefit and safety on No.12a lymph nodes (LNs) dissection for gastric cancer patients. This study was aimed to evaluate this issue for patients with distal or total gastrectomy. Patients were retrospectively divided into 12aD+ group (with No.12a dissection) and 12aD–group (without No.12a dissection). Clinicopathologic characteristics, survival rate, morbidity and mortality were compared. There were 670 patients in 12aD+ group, while 567 in 12aD–group. The baselines between the two groups were comparable. The No.12a LNs metastasis ratio was 11.6% and higher in lower third tumor. The metastasis of No.5 LNs, N stage and M stage were correlated to metastasis of No.12a LNs. There was no difference in morbidity nor mortality between the two groups. The 5-year overall survival rates (5-y OS) were 59.6% and 55.1% in 12aD+ group and 12aD–group respectively (P = 0.075). The 5-y OS of patients with negative and positive No.12a LNs were 62.3% and 24.1%. The survival of stage III patients with No.12a positive was better than that of stage IV patients. The 5-y OS were better in 12aD+ group for patients with ages more than 60, lower third tumor, distal gastrectomy, N3 status, or III stages compared with 12aD–group. No.12a lymphadenectomy was independently better prognostic factors for stage III patients. No.12a LNs metastasis should not be considered as distant metastasis. No.12a lymphadenectomy can be performed safely and should be indicated for potentially curable progressive stage tumors requiring distal gastrectomy and might be reserved in patients with stage I or II, or upper third tumor.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 7930